In today’s recent session, 0.46 million shares of the Altimmune Inc (NASDAQ:ALT) have been traded, and its beta is 0.08. Most recently the company’s share price was $6.10, and it changed around -$0.13 or -2.09% from the last close, which brings the market valuation of the company to $433.53M. ALT at last check was trading at a discount to its 52-week high of $14.84, offering almost -143.28% off that amount. The share price’s 52-week low was $2.09, which indicates that the recent value has risen by an impressive 65.74% since then. We note from Altimmune Inc’s average daily trading volume that its 10-day average is 2.12 million shares, with the 3-month average coming to 2.48 million.
Altimmune Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.50. If we narrow it down even further, the data shows that 0 out of 1 analysts rate the stock as a Sell; another 0 rate it as Overweight. Among the rest, 0 recommended ALT as a Hold, whereas 1 deemed it a Buy, and 0 rated it as Underweight. Altimmune Inc is expected to report earnings per share of -0.35 for the current quarter.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Altimmune Inc (NASDAQ:ALT) trade information
Instantly ALT has been showing red trend so far today with a performance of -2.09% on intraday trading today. The performance over the last five days has remained in the red territory. The rise to weekly highs of 6.49 on recent trading dayincreased the stock’s daily price by 6.01%. The company’s shares are currently down -45.78% year-to-date, but still down -0.65% over the last five days. On the other hand, Altimmune Inc (NASDAQ:ALT) is -1.61% down in the 30-day period. We can see from the shorts that 21.87 million shares have been sold at a short interest cover period of 9.52 day(s).
The consensus price target as assigned by Wall Street analysts is $25, which translates to bulls needing to increase their stock price by 75.6% from its current value. Analyst projections state that ALT is forecast to be at a low of $12 and a high of $35.
Altimmune Inc (ALT) estimates and forecasts
Altimmune Inc share prices are performing particularly well not compared to other companies within the same industry. As is evident from the statistics, the company’s shares have fallen -29.15 percent over the past six months and at a 4.20% annual growth rate that is well below the industry average of 19.40%. Moreover, analysts have decided to roll up on their fiscal year 2024 revenue estimates. The rating firms predict that it will gain 10.30% in revenue this quarter, and will report an increase of 38.90% in the next quarter. The year-over-year growth rate is expected to be -97.70%, down from the previous year.
The company’s sales for the same quarters a year ago were 362k and 37k respectively.
Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 35.74%.
ALT Dividends
Altimmune Inc’s next quarterly earnings report is expected to be released on 2024-Nov-05.
Altimmune Inc (NASDAQ:ALT)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 0.80% of Altimmune Inc shares, and 60.59% of them are in the hands of institutional investors. The stock currently has a share float of 61.07%. Altimmune Inc stock is held by 239.0 institutions, with BLACKROCK INC. being the largest institutional investor. By 2024-06-30, it held 7.5155% of the shares, which is about 5.32 million shares worth $35.39 million.
VANGUARD GROUP INC, with 6.9301% or 4.91 million shares worth $32.63 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
